Organon & Co. OGN

Why MIUDELLA’s FDA review matters for Organon stock Organon (OGN) just picked up fresh attention after the FDA accepted a supplemental application to extend use of MIUDELLA, a copper IUD that Organon licensed globally earlier this year. The device is already indicated for pregnancy prevention for up to 3 years, with an extended duration review underway and commercial availability targeted for late 2026. For investors watching Organon stock, this product sits squarely in the women’s health...

Organon (NYSE: OGN) received FDA acceptance to review a supplemental New Drug Application for its hormone free contraceptive device MIUDELLA. The company entered an exclusive global licensing agreement for MIUDELLA, aiming to expand access to hormone free contraception across markets. Organon plans commercial availability of MIUDELLA as a longer duration contraceptive option, subject to regulatory review outcomes and launch execution. Beyond the MIUDELLA sNDA review and new global license,...